{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-23-000021","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2023-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.744313+00:00","generated_at":"2026-06-18T03:46:10.288415+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GeneDx Q4 revenue $61.4M (+6.2% YoY), full-year net loss $667.6M; 2023 guidance reiterated","bullets":["Combined revenue $61.4M in Q4 (+6.2% YoY); full year $234.7M (+10% YoY). Net operating loss $667.6M for FY22.","Pro forma continuing ops revenue $45.8M in Q4 (+32% YoY); full year $171.0M (+38% YoY). Adjusted gross margin 41% in Q4.","Completed $150M public offering in Jan 2023; cash position $138.3M at Dec 31, 2022.","Reiterated FY2023 guidance: revenue $205-220M, cash burn $130-145M, targeting profitability in 2025.","Whole exome sequencing volume grew 18.8% YoY in Q4; total volume up 25.8%."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-23-000021","json":"https://secwatch.observer/filing/0001818331-23-000021.json","markdown":"https://secwatch.observer/filing/0001818331-23-000021.md","text":"https://secwatch.observer/filing/0001818331-23-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000021/0001818331-23-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833123000021/smfr-20230314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T03:46:10.288415+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}